Novo Nordisk to Sue Hims & Hers for Wegovy Compounding (HIMS, NVS)

Novo Nordisk announced it will take legal and regulatory action against Hims & Hers after the telehealth firm plans to begin offering compounded copies of its FDA-approved Wegovy at $49 per month. "The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety," Novo Nordisk said in a statement. "Novo Nordisk will take legal and regulatory action to protect patients, our intellectual property and the integrity of the U.S. gold-standard drug approval framework," the company added. Novo Nordisk is the only company manufacturing Wegovy formulated with SNAC technology, which facilitates semaglutide oral absorption.